- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07941544
Njinsky Ambispective Cellular Product Safety and Outcomes Registry
Safety and Disease-Specific Outcomes Following Routine-Care Use of Cultured UCMSCs and/or Autologous Uncultured SVF Across Multiple Indications: An Ambispective Observational Registry
This ambispective observational registry will describe safety events, treatment patterns, and disease-specific clinical assessments among patients receiving cultured umbilical cord mesenchymal stromal cells (UCMSCs), autologous uncultured stromal vascular fraction (SVF), or both as part of routine care at Njinsky Medical Centre. The registry includes separate cohorts for retinitis pigmentosa, autism spectrum disorder, female infertility conditions, and azoospermia. The retrospective component will use eligible routine-care records from 1 January 2020 through 30 November 2026. Prospective enrollment is planned from 1 December 2026 through 31 December 2030, with follow-up at 1, 3, 6, 12 and 24 months after the last treatment session. Patients may be followed by phone or in person. The study will not assign treatment or require additional tests; it will record measures obtained in routine care and information reported or documented at follow-up. Results will be described separately by condition and actual product exposure. The registry is not designed by itself to establish that a product caused a clinical outcome.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Design and setting. Single-centre, ambispective observational cohort/patient registry at Njinsky Medical Centre, Lahore. The retrospective component covers routine-care records from 1 January 2020 through 30 November 2026. The prospective component is planned to begin 1 December 2026 and enroll through 31 December 2030. Follow-up is planned at 1, 3, 6, 12 and 24 months after the participant's last administration. Because the last prospective administrations may occur at the end of 2030, final 24-month follow-up and study completion are estimated by 31 December 2032.
Routine-care status. Clinicians and patients make treatment decisions in usual care; the research protocol does not assign a product, dose, route, or schedule. Patients are included if they have a qualifying indication, receive eligible routine-care administration, and permit inclusion under the consent/authorization and ethics process. Existing approvals and consents are reported by the sponsor as covering both retrospective review and prospective follow-up; enter the exact committee reference and dates before PRS release.
Population and cohorts. Four disease-specific cohorts will be described separately: retinitis pigmentosa; autism spectrum disorder (including minors); female infertility conditions, primarily diminished/low ovarian reserve, secondary infertility and amenorrhea; and azoospermia. Clinical diagnoses and eligibility are determined in routine care. Record relevant subtypes and diagnostic details when available. Participants may have multiple indications; count each unique person once in total enrollment and define a primary/index indication for cohort-level summaries, while retaining secondary indication data where applicable.
Exposure. Participants may receive cultured UCMSCs, autologous uncultured SVF, or both. Exposure is recorded session-by-session, including product, date, route, dose/source amount, sequence, and whether products were given at the same or different sessions. Patients may decline liposuction; treatment selection is not randomized. The two products are not assumed equivalent. Disease-specific outcomes and safety will be reported by indication and actual exposure history where data allow.
Data collection. No tests or visits are required solely for the registry. The team will abstract existing clinical information and record outcomes available from routine care. Follow-up may be by telephone or in-person visit. Staff monitor participants for up to 10 hours after each administration and ask specifically about adverse effects at follow-up. Tests, scales and assessments vary by diagnosis and are recorded only when performed as part of care.
Analysis. Analyses will be descriptive and stratified by disease cohort and exposure pattern. Report denominators, available follow-up, missingness and number of sessions. Because treatment is not randomized and selection may reflect clinician judgement, disease severity, availability or patient preference, comparisons and before/after changes will not be interpreted as proof of causal efficacy.
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiesteder
-
-
Punjab Province
-
Lahore, Punjab Province, Pakistan, 54000
- Njinsky Medical Centre
-
Kontakt:
- Zania Urooj, Masters
- Telefonnummer: +923033371111
- E-mail: zania.urooj@njinsky.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Patients receiving routine care at Njinsky Medical Centre in Lahore who have a documented diagnosis of retinitis pigmentosa, autism spectrum disorder, a female fertility condition (primarily diminished or low ovarian reserve, secondary infertility, or amenorrhea), or azoospermia, and who receive cultured UCMSCs and/or autologous uncultured SVF. The registry includes eligible participants whose records fall within the retrospective period from January 1, 2020 through November 30, 2026, and eligible participants enrolled prospectively from December 1, 2026 through December 31, 2030. Children with autism spectrum disorder may be included with guardian permission and assent as required by the approved process. The registry does not assign treatment or require additional tests.
Beskrivelse
Inclusion Criteria:
- The clinical record documents a diagnosis in at least one registry cohort: retinitis pigmentosa, autism spectrum disorder, a female fertility condition, or azoospermia.
- The participant received at least one routine-care administration of cultured umbilical cord mesenchymal stromal cells, autologous uncultured stromal vascular fraction, or both at Njinsky Medical Centre during the registry period.
- Retrospective records are included only when use of the data is covered by consent or other authorization approved by the Institutional Review Board.
- Prospective participants agree to registry inclusion under the approved consent process.
- For minors, guardian permission and age-appropriate assent are obtained as required by the approved process.
Exclusion Criteria:
- No qualifying diagnosis is documented.
- No eligible routine-care administration can be verified.
- There is no valid consent or other Institutional Review Board-approved basis to use the participant's data.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: OTHER
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Retinitis Pigmentosa
Patients diagnosed with retinitis pigmentosa in routine care who receive an eligible UCMSC and/or SVF administration at Njinsky Medical Centre. |
Routine-care exposure observed by the registry. The study does not assign treatment. Cultured umbilical cord mesenchymal stromal cells are administered at 1 million cells/kg total. Half is given intravenously and half by the indication-specific route: sub-Tenon for retinitis pigmentosa, intrathecal for autism spectrum disorder, intraovarian for female infertility, or intratesticular for azoospermia. The treating clinician selects the route and schedule. Actual dose, route, dates, and sessions are recorded.
Andre navne:
Routine-care exposure observed by the registry. The study does not assign treatment. Autologous uncultured stromal vascular fraction is prepared from approximately 100 to 120 mL of adipose tissue. The resulting pellet is resuspended in saline. Half is administered intravenously and half by the indication-specific route: sub-Tenon for retinitis pigmentosa, intrathecal for autism spectrum disorder, intraovarian for female infertility, or intratesticular for azoospermia. The treating clinician selects the route and schedule. Actual preparation, route, dates, and sessions are recorded.
Andre navne:
|
|
Autism Spectrum Disorder
Patients diagnosed with autism spectrum disorder in routine care who receive an eligible administration. Children may be included; use guardian permission and age-appropriate assent as required by the IRB-approved process. |
Routine-care exposure observed by the registry. The study does not assign treatment. Cultured umbilical cord mesenchymal stromal cells are administered at 1 million cells/kg total. Half is given intravenously and half by the indication-specific route: sub-Tenon for retinitis pigmentosa, intrathecal for autism spectrum disorder, intraovarian for female infertility, or intratesticular for azoospermia. The treating clinician selects the route and schedule. Actual dose, route, dates, and sessions are recorded.
Andre navne:
|
|
Female infertility conditions
Patients receiving routine care for female fertility conditions, primarily diminished/low ovarian reserve, secondary infertility and amenorrhea, who receive an eligible administration. Record the specific diagnosis per patient. |
Routine-care exposure observed by the registry. The study does not assign treatment. Cultured umbilical cord mesenchymal stromal cells are administered at 1 million cells/kg total. Half is given intravenously and half by the indication-specific route: sub-Tenon for retinitis pigmentosa, intrathecal for autism spectrum disorder, intraovarian for female infertility, or intratesticular for azoospermia. The treating clinician selects the route and schedule. Actual dose, route, dates, and sessions are recorded.
Andre navne:
Routine-care exposure observed by the registry. The study does not assign treatment. Autologous uncultured stromal vascular fraction is prepared from approximately 100 to 120 mL of adipose tissue. The resulting pellet is resuspended in saline. Half is administered intravenously and half by the indication-specific route: sub-Tenon for retinitis pigmentosa, intrathecal for autism spectrum disorder, intraovarian for female infertility, or intratesticular for azoospermia. The treating clinician selects the route and schedule. Actual preparation, route, dates, and sessions are recorded.
Andre navne:
|
|
Azoospermia
Patients diagnosed with azoospermia in routine care who receive an eligible administration. Record obstructive/non-obstructive classification when available. |
Routine-care exposure observed by the registry. The study does not assign treatment. Cultured umbilical cord mesenchymal stromal cells are administered at 1 million cells/kg total. Half is given intravenously and half by the indication-specific route: sub-Tenon for retinitis pigmentosa, intrathecal for autism spectrum disorder, intraovarian for female infertility, or intratesticular for azoospermia. The treating clinician selects the route and schedule. Actual dose, route, dates, and sessions are recorded.
Andre navne:
Routine-care exposure observed by the registry. The study does not assign treatment. Autologous uncultured stromal vascular fraction is prepared from approximately 100 to 120 mL of adipose tissue. The resulting pellet is resuspended in saline. Half is administered intravenously and half by the indication-specific route: sub-Tenon for retinitis pigmentosa, intrathecal for autism spectrum disorder, intraovarian for female infertility, or intratesticular for azoospermia. The treating clinician selects the route and schedule. Actual preparation, route, dates, and sessions are recorded.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Participants with one or more adverse effects reported or documented after administration
Tidsramme: During observation for up to 10 hours after each administration, and at follow-up 1, 3, 6, 12, and 24 months after the participant's last session.
|
Number and proportion of participants with at least one adverse effect recorded during post-administration observation or follow-up. Staff monitor participants for up to 10 hours after each administration and ask participants or caregivers about adverse effects at follow-up. Event type and clinical course are recorded when available. The registry describes events after administration and does not assume causality. |
During observation for up to 10 hours after each administration, and at follow-up 1, 3, 6, 12, and 24 months after the participant's last session.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Routine visual acuity assessments
Tidsramme: At baseline and at routine-care follow-up 1, 3, and 6 months after the participant's last session, when the measure is obtained.
|
Visual acuity values recorded in routine care. Record the test result and eye assessed. The registry does not require additional visual acuity testing. |
At baseline and at routine-care follow-up 1, 3, and 6 months after the participant's last session, when the measure is obtained.
|
|
Routine fundus examination findings
Tidsramme: At baseline and at routine-care follow-up 1, 3, 6, 12, and 24 months after the participant's last session, when the measure is obtained.
|
Findings from fundus examinations documented in routine care. The registry does not require additional examinations. |
At baseline and at routine-care follow-up 1, 3, 6, 12, and 24 months after the participant's last session, when the measure is obtained.
|
|
Routine optical coherence tomography findings
Tidsramme: At baseline and at routine-care follow-up 6 months after the participant's last session, when the measure is obtained.
|
OCT results documented in routine care. Record available findings or measurements; the registry does not require additional imaging. |
At baseline and at routine-care follow-up 6 months after the participant's last session, when the measure is obtained.
|
|
National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25)
Tidsramme: At baseline and at routine-care follow-up 1, 3, 6, 12, and 24 months after the participant's last session, when the measure is obtained.
|
Measure: National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) Composite Score Description: Contains a total of 25 questions and measures patient-reported vision-related functioning and quality of life. The composite score ranges from 0 to 100, with higher scores indicating better vision-related functioning. |
At baseline and at routine-care follow-up 1, 3, 6, 12, and 24 months after the participant's last session, when the measure is obtained.
|
|
Autism Treatment Evaluation Checklist score ATEC
Tidsramme: At baseline and at routine-care follow-up 1, 3, 6, 12, and 24 months after the participant's last session, when the measure is obtained.
|
Measure: The Autism Treatment Evaluation Checklist (ATEC), Total Score Description: Measures reported autism-related symptoms across communication, sociability, sensory and cognitive awareness, and health and behavior domains. The total score ranges from 0 to 179. Higher scores indicate greater reported symptom burden; lower scores indicate fewer reported symptoms. |
At baseline and at routine-care follow-up 1, 3, 6, 12, and 24 months after the participant's last session, when the measure is obtained.
|
|
Childhood Autism Rating Scale score (CARS)
Tidsramme: At baseline and at routine-care follow-up 1, 3, 6, 12, and 24 months after the participant's last session, when the measure is obtained.
|
Measure: The Childhood Autism Rating Scale (CARS), Total Score Description: Measures autism-related behaviors and symptom severity. The total raw score ranges from 15 to 60, with higher scores indicating greater symptom severity. |
At baseline and at routine-care follow-up 1, 3, 6, 12, and 24 months after the participant's last session, when the measure is obtained.
|
|
Social Responsiveness Scale score, Second Edition (SRS-2)
Tidsramme: At baseline and at routine-care follow-up 1, 3, 6, 12, and 24 months after the participant's last session, when the measure is obtained.
|
Measure: Social Responsiveness Scale, Second Edition (SRS-2) Total Score Description: Measures social responsiveness and autism-related social impairment. The total raw score ranges from 0 to 195, with higher scores indicating greater social impairment. |
At baseline and at routine-care follow-up 1, 3, 6, 12, and 24 months after the participant's last session, when the measure is obtained.
|
|
Vineland Adaptive Behavior Scales, Third Edition (Vineland-3)
Tidsramme: At baseline and at routine-care follow-up 1, 3, 6, 12, and 24 months after the participant's last session, when the measure is obtained.
|
Measure: Vineland Adaptive Behavior Scales, Third Edition (Vineland-3) is a Comprehensive Form Adaptive Behavior Composite and Domain Standard Scores Description: The Vineland-3 Comprehensive Form assesses adaptive behavior, including communication, daily living skills, and socialization. Adaptive Behavior Composite and domain standard scores range from 20 to 140. Higher scores indicate stronger adaptive functioning relative to the age-based norm group |
At baseline and at routine-care follow-up 1, 3, 6, 12, and 24 months after the participant's last session, when the measure is obtained.
|
|
Routine fertility hormone profile results
Tidsramme: At baseline and at routine-care follow-up 6 months after the participant's last session, when the measure is obtained.
|
Results of hormonal tests ordered in routine care for participants with diminished or low ovarian reserve, secondary infertility, or amenorrhea. Record the test name, result, and date when available. The registry does not require additional laboratory testing. |
At baseline and at routine-care follow-up 6 months after the participant's last session, when the measure is obtained.
|
|
Menstrual status and menstrual mapping
Tidsramme: At baseline and at routine-care follow-up 1, 3, 6, 12, and 24 months after the participant's last session, when the measure is obtained.
|
Menstrual status and cycle information recorded in routine care, including amenorrhea or changes in menstrual pattern when documented. |
At baseline and at routine-care follow-up 1, 3, 6, 12, and 24 months after the participant's last session, when the measure is obtained.
|
|
Routine pelvic ultrasound findings
Tidsramme: At baseline and at routine-care follow-up 6 months after the participant's last session, when the measure is obtained.
|
Pelvic ultrasound findings documented during routine fertility care. Record available findings; the registry does not require additional ultrasound examinations. |
At baseline and at routine-care follow-up 6 months after the participant's last session, when the measure is obtained.
|
|
Routine hormonal and laboratory results
Tidsramme: At baseline and at routine-care follow-up 6 months after the participant's last session, when the measure is obtained.
|
Hormonal profile and other laboratory results obtained during routine care for azoospermia. Record each test name, result, and date when available. The registry does not require additional tests. |
At baseline and at routine-care follow-up 6 months after the participant's last session, when the measure is obtained.
|
|
Routine ultrasound findings
Tidsramme: At baseline and at routine-care follow-up 6 months after the participant's last session, when the measure is obtained.
|
Ultrasound findings documented during routine care for azoospermia. Record available findings; the registry does not require additional imaging. |
At baseline and at routine-care follow-up 6 months after the participant's last session, when the measure is obtained.
|
|
Testicular sperm aspiration findings
Tidsramme: At baseline and at routine-care follow-up 6 months after the participant's last session, when the measure is obtained.
|
TESA findings, including whether sperm were identified, when the procedure is performed as part of routine care. The registry does not require TESA. |
At baseline and at routine-care follow-up 6 months after the participant's last session, when the measure is obtained.
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Generelle publikationer
- Zhankina R, Baghban N, Askarov M, Saipiyeva D, Ibragimov A, Kadirova B, Khoradmehr A, Nabipour I, Shirazi R, Zhanbyrbekuly U, Tamadon A. Mesenchymal stromal/stem cells and their exosomes for restoration of spermatogenesis in non-obstructive azoospermia: a systemic review. Stem Cell Res Ther. 2021 Apr 6;12(1):229. doi: 10.1186/s13287-021-02295-9.
- Confalonieri F, La Rosa A, Ottonelli G, Barone G, Ferraro V, Di Maria A, Romano M, Randazzo A, Vallejo-Garcia JL, Vinciguerra P, Petrovski G. Retinitis Pigmentosa and Therapeutic Approaches: A Systematic Review. J Clin Med. 2024 Aug 9;13(16):4680. doi: 10.3390/jcm13164680.
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Genitale sygdomme
- Psykiske lidelser
- Patologiske processer
- Kønssygdomme, mandlige
- Mandlige urogenitale sygdomme
- Genetiske sygdomme, medfødte
- Øjensygdomme
- Øjensygdomme, arvelig
- Neuroudviklingsforstyrrelser
- Børns udviklingsforstyrrelser, gennemgående
- Nethindesygdomme
- Nethindedystrofier
- Nethindedegeneration
- Menstruationsforstyrrelser
- Infertilitet, Mand
- Infertilitet
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Patologiske tilstande, tegn og symptomer
- Autismespektrumforstyrrelse
- Autistisk lidelse
- Retinitis Pigmentosa
- Amenoré
- Azoospermi
- Azoospermi, ikke-obstruktiv
Andre undersøgelses-id-numre
- NMC/IRB-01/26
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .